BBOT BBOT
Company Profile ↓Company Overview
BBOT (BBOT) is a publicly traded company listed on with a market capitalization of $716.73M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -5.68% |
| 6 Months: | -24.58% |
| 3 Months: | +8.34% |
| 1 Month: | +8.08% |
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)57.56 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 34.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | -66.70K | -152.34K | -19.66M | -23.14M | -1.12M | -49.18M | -46.18M |
| Net Income | -15.44M | -21.82M | -17.32M | -22.05M | -28.43M | -44.76M | -42.11M |
| Diluted EPS | - | - | -1,562.18 | -54.23 | - | -1.03 | -526.11 |
| R&D Expense | - | - | 17.89M | 20.64M | - | 35.05M | 39.80M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Income | -41.69K | -80.86M | -145.82M |
| Net Income | -41.69K | -74.28M | -134.04M |
| Diluted EPS | - | -5,756.41 | -4.30 |
| R&D Expense | - | 73.11M | 121.20M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 5.94M | 164.30M | 448.38M |
| Current Assets | - | 3.94M | 158.69M | 432.40M |
| Cash & Equivalents | - | 250.00K | 30.85M | 373.69M |
| Inventory | - | - | - | - |
| Receivables | - | 1.72M | 81.00K | 386.00K |
| Total Liabilities | - | 121.58M | 342.94M | 37.28M |
| Current Liabilities | - | 16.77M | 19.58M | 35.04M |
| Long Term Debt | - | - | - | - |
| Total Debt | - | - | 0 | 2.77M |
| Total Equity | -21.88K | -115.64M | -178.64M | 411.10M |
| Shares Outstanding | - | 79.20M | 79.20M | 79.99M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -55.03M | -113.89M |
| Investing Cash Flow | -120.53M | 73.33M |
| Financing Cash Flow | 206.29M | 383.40M |
| Capital Expenditure | -49.00K | -606.00K |
| Free Cash Flow | -55.08M | -114.50M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | 0.0% | 41.6% | -32.6% |
| ROCE % | 0.4% | -55.9% | -35.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BBOT
ETFs Investing in BridgeBio Oncology Therapeutics, Inc. Stocks - TradingView
<a href="https://news.google.com/rss/articles/CBMiY0FVX3lxTFBvejdwWnYtdnluYTBtcHZYWjV3b1hBMW1rWGJmV01DamljeHloVnlKMjVJVm00U2RSVjJUc0p2dnFQTThnYnZSUFBmZnFaYUNfbHhldDJLMWpBRGt2d1ptdGp2MA?oc=5" target="_blank">ETFs Investing in BridgeBio Oncol…
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQRlFTYjlzY0hvV1pUX2JWbkpnNHU5NkZmYm9ham9yaFlMWkFnOWpSR3FUWUlZZnJnXzhfSFFzTzJMVThDZUFxTUxyZ3ZtWHMzWWtueTJEMEs0bFl2Q1JEOTlBcVRQbmdrWHAxa3ZzQWtUYWNoM29mdElpTkZpMjNrYTRtLWp6a2lCYTJjNT…
BBOT shakes up leadership as RAS competitors get more visibility - BioSpace
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNckNZQTVUOC1lc0tGZTNHMEFqdzFfVlU2RURwdGwxQm9kc0J3azZudVRCcEpyX0gyTXByWW53aEZHeDJaSzRMUGJseHgyaWN6TXVSUDRiUVFBVnA1YjhmcmxOaWt2NExHeWRvNlcxQnNzNFp0RW84T1FhMl8tME1hZUU1YTdGdmhpVTk2en…
BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOaEcwOFlRUzJjcHhkTDdkRndCOHh6R2FSSFJfTDJIbDFjbGlTai1oM2FwdDZqWHlPaFN6Y3R1b2RuLWFzMlRlUW5LMmxycGR0NFl2cEgzZUV0RDJHNDIzOGkzYS1NWENaN2RwQ2Z0T3ZjcTVuUDNVVDlOeXdpTHZ3X3EtNDhBaUN2bC15ZV…
BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxNZ2poemV2NmhxNWZLRnVSenZBdnBfSFhjWW91cF9NWlZ3THRScVFqUUF2cUlXMHRVVGs3ZzRsLU5GOG0zY1lVTEZFY3JfUDVGbDdnaThMTmdCOGhBeFRlWk9KbWphLTlzcGtZVDNqblJyRy15X2tfbUs1UnFmSXhKcUJna19DVU43UU9SQk…
Which stocks are gapping on Wednesday? - ChartMill
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNajZCU0RFdjFVRThhN1dadDZfdXNqaHJPLVZ5ZTRYMlo2TEZrcjZvaTVVRmlRbVp1R3JwODlNRklPMy1MT1lJcDFQdjc3WEctVHluQkdraHRvWGhUcUZBd2RueWQ2QjhOY1JZc3dWOVJwcVg5bnlxTEhON1lwakJ3ajVxUU85bTRhY0ZUem…
BBOT — Frequently Asked Questions
What is the current share price of BBOT?
As of 2026-08-05 17:25 PDT, BBOT trades at $8.96 on NASDAQ/NYSE. Its 52-week range is $7.12 to $13.73.
What is the market capitalisation of BBOT?
BBOT has a market capitalisation of $716.73M on NASDAQ/NYSE.
What is the P/E ratio of BBOT?
BBOT trades at a trailing price-to-earnings (P/E) ratio of -2.08. Its price-to-book (P/B) ratio is 1.74.
What is the return on equity (ROE) of BBOT?
BBOT has a return on equity (ROE) of -32.61%. Its return on capital employed (ROCE) is -35.28%.
Is BBOT a good stock to buy?
This page provides a data-driven analysis of BBOT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.